The Use of ADV6209 for Premedication in Pediatric Anesthesia
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral
Category: Drug delivery
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today
Special issue: Nanoconstructs Based on Cyclodextrins
A special issue in Nanomaterials, an open access journal of MDPI will focus on native or modified CDs leading to
New book: Nanosponges: Synthesis and Applications
Wiley has recently published a book on nanosponges edited by Francesco Trotta and Andrea Mele. The book gives an excellent
Rabbits in cyclodextrin research
Rabbits are small animals, favorite models in pharmaceutical research. In Scopus search 554 hits were found for the keywords: “cyclodextrin
Making Pharmaceuticals EXHIBITION & CONFERENCE
The Leading UK Pharmaceutical Exhibition and Conference will be held on 30 April –1 May Ricoh Arena, Coventry, UK. The
Host-guest chemistry for the treatment of leishmania
Human leishmaniasis is an infectious parasitic disease endemic to about 90 countries by over 20 different Leishmaniasis species. It is
Effect of CD on the antiaging drug: rapamycin
Rapamycin (also known as sirolimus) is a macrolide compound produced by the bacterium Streptomyces hygroscopicus. It is immunosuppressant used to
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of
Sage Therapeutics Announces FDA Approval of ZULRESSO™ (SBECD-enabled brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms